CRISPR Medicine

AvenCell

Company Type: Therapeutics

Main focus: Development of autologous CAR-T cell therapies

Company stage: Pre-clinical

Diseases: Neurodegenerative disorders

Genome-editing tool: CRISPR-Cas

Funding stage: Series A

Location: Dresden, Germany

Website: https://avencell.com/

Pipeline: https://avencell.com/pipeline/

Partners:


AvenCell brings together switchable universal T-cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellia Therapeutics proprietary CRISPR-Cas9-based allogeneic platform to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.

See the full view ...